Peak Bio, Inc. (PKBO) Financial Statements (2024 and earlier)

Company Profile

Business Address 4900 HOPYARD ROAD, SUITE 100
PLEASANTON, CA 94588
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments655329
Cash and cash equivalents655329
Prepaid expense2,56371
Derivative instruments and hedges, assets 13 
Total current assets:3,231401
Noncurrent Assets
Operating lease, right-of-use asset 3,681 
Property, plant and equipment377 
Asset, held-in-trust  57,506
Restricted cash and investments240 
Other noncurrent assets2 
Total noncurrent assets:4,29957,506
TOTAL ASSETS:7,53057,907
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,656326
Accounts payable3,618 
Accrued liabilities2,038326
Debt 1,375 
Derivative instruments and hedges, liabilities166 
Due to related parties 1,962112
Other undisclosed current liabilities1,642 
Total current liabilities:10,801438
Noncurrent Liabilities
Liabilities, other than long-term debt4,8231,975
Other liabilities791 
Operating lease, liability 3,507 
Derivative instruments and hedges, liabilities5251,975
Total noncurrent liabilities:4,8231,975
Total liabilities:15,6242,413
Equity
Equity, attributable to parent(8,094)(2,006)
Common stock20
Additional paid in capital17,220 
Accumulated other comprehensive income30 
Accumulated deficit(25,346)(2,006)
Other undisclosed equity  57,500
Total equity:(8,094)55,494
TOTAL LIABILITIES AND EQUITY:7,53057,907

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Revenues608481
Other income 481
Gross profit:608481
Operating expenses(12,456)(969)
Other undisclosed operating income (loss) (481)
Operating loss:(11,848)(969)
Nonoperating income (expense)(1,315)475
Investment income, nonoperating 475
Other nonoperating income (expense)368 
Interest and debt expense(467) 
Other undisclosed loss from continuing operations before equity method investments, income taxes  
Loss from continuing operations before equity method investments, income taxes:(13,630)(494)
Other undisclosed income from continuing operations before income taxes467 
Loss from continuing operations before income taxes:(13,163)(494)
Income tax benefit74 
Loss from continuing operations:(13,089)(494)
Loss before gain (loss) on sale of properties:(494)
Net loss:(13,089)(494)
Other undisclosed net income attributable to parent  6
Net loss available to common stockholders, diluted:(13,089)(488)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(13,089)(494)
Other comprehensive income (loss)(59) 
Other undisclosed comprehensive loss  
Comprehensive loss, net of tax, attributable to parent:(13,148)(494)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: